Press release 2023-08-25

Genetic Analysis AS ramps up its market presence for the GA-map® microbiome testing in the US

OSLO, NORWAY – August 25, 2023: Microbiome diagnostics specialist, Genetic Analysis AS (“GA”) has through its distributor Eagle Biosciences Inc, entered an agreement with an undisclosed partner, a high-volume lab company providing laboratory diagnostics to clinics, public health departments and research universities in the US. The partner is expected to launch the standardized and validated GA-map® as a testing service during Q4 2023. The partnership perfectly aligns with GA’s strategy to accelerate growth through new high-volume labs and marks an important step forward in GA’s business expansion in the US microbiome market.

Ronny Hermansen, CEO, Genetic Analysis, comments:
“GA is proud to announce an additional new partner in the US – the biggest microbiome testing market in the world. The need for quick and accurate microbiome diagnostics is increasing rapidly, we are thrilled to partner up with a new lab to accelerate our growth in this advanced market. Expanding the number of GA-map® platform installations into high-volume labs is of great importance for us as it drives top-line growth for current products while cementing GA as the preferred partner for Pharma and diagnostic companies who want to co-develop new tests on the GA-map® platform – thus securing long-term growth in a fast-growing market.”

GA’s top priority is to continue its business expansion and accelerate growth through new partnerships. With the US microbiome market being the most advanced, GA is proud to announce its next partnership in this market. The recent FDA approval of microbiome-altering drugs has accelerated the need for routine microbiome diagnostics, and the awareness of the importance of a healthy microbiome is rapidly increasing rapidly. The GA-map® is a standardized and validated diagnostic platform that gives immediate results and is compared to a healthy reference population.

Dan Keefe, Founder and President, Eagle Biosciences, comments:
“Eagle Biosciences is thrilled to be a part of this exciting collaboration with Genetic Analysis and a new US lab. We take pride in providing the highest quality immunoassays, antibodies, and proteins since 2010. Offering labs in the US the GA-map®, a standardized and validated microbiome testing service, perfectly aligns with our commitment to delivering precision diagnostic solutions.”

About the US microbiome market
The US is the world’s largest microbiome market and the need for gut microbiome assessments is rapidly increasing. This is due to the rising prevalence of gastrointestinal disorders and the increasing focus on the impact of the microbiome in many other diseases and fueled by the large number of biotechnology and pharmaceutical companies involved in research and development activities related to the microbiome. The Human Microbiome Market (www.marketsandmarkets.com) states in a report published in April 2022 that the global market for Microbiome will reach USD 269 million in 2023 and USD 1.370 million in 2029 at a CAGR (Compound Annual Growth Rate) of 31,1% during the forecast period 2023 to 2029.
For further information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com

Eilert Aamodt, Chief Financial Officer
E-mail: ea@genetic-analysis.com

About Eagle Biosciences, Inc.:
Since 2010, Eagle Biosciences has been providing the highest quality and best value immunoassays, antibodies,
and proteins available on the market. There are many suppliers of ELISAs and other assays and hundreds of
thousands of products to choose from, but EagleBio only offers products that deliver the maximum level of
performance and provide reliable and trusted results.

For more information Eagle Biosciences, Inc.:  www.EagleBio.com

About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field
with more than 15 years of expertise in research and product development. The unique GA-map® platform is
based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number
of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-
map® software algorithm. This enables immediate results without the need for further bioinformatics work.
GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is
committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA
employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics,
molecular biology, and bioengineering.

For more information:  www.genetic-analysis.com

Interested in reading more about GA’s products? Please visit ga-map.com